News - 14 Sep `20AVITA Medical: clinical trials in the USA


First patient enrolled in AVITA Therapeutic’s study in Miami earlier this week. The prospective study is evaluating the RECELL system for repigmentation of patients with stable vitiligo, meaning they have not had new vitiligo lesions or lesions that have expanded for at least one year.

AVITA’s technology creates an autologous suspension from a piece of the patient's own normal skin in under 30 minutes, to spray pigment-producing cells onto vitiligo lesion.

The company is about to begin two multi-center clinical trials in the USA (details 1 and details 2)

For more information, please contact: Elizabeth Kirshner at 661-367-9180 or


      FAQOther Questions

      • Which diseases most commonly accompany vitiligo?

        According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...

      • What is vitiligo?

         Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Cont...

      • What's better: laser or phototherapy?

        In a recent study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA and PUVA. No significa...